Yupelri is a medication used to treat bronchopulmonary dysplasia (BPD) in preterm infants. It is an inhaled, nebulized form of a specific type of steroid, a corticosteroid, delivered directly to the lungs. The active ingredient in Yupelri is the synthetic glucocorticoid, budesonide [1].
How does Yupelri work to treat bronchopulmonary dysplasia?
Yupelri works by reducing inflammation in the airways and lungs of infants with BPD. BPD is a chronic lung disease that often affects premature babies who have received prolonged mechanical ventilation and oxygen therapy. This therapy can damage the developing lungs, leading to inflammation and scarring. Budesonide, the active component of Yupelri, is a potent anti-inflammatory agent. By delivering the medication directly to the lungs via nebulization, it targets the inflamed areas, helping to alleviate symptoms and improve lung function [1].
When can infants start receiving Yupelri treatment?
Treatment with Yupelri typically begins after an infant has been on mechanical ventilation for at least 10 days. This timing is based on clinical trials that established the efficacy of the drug in infants who have already experienced some degree of lung injury associated with mechanical ventilation. The goal is to intervene before lung damage becomes irreversible and to support lung development [1].
What are the potential side effects of Yupelri?
As with many medications, Yupelri can have side effects. The most common ones observed in clinical studies include sepsis, increased heart rate, gastrointestinal bleeding, and urinary tract infections. Other potential side effects may include pneumonia, hyperglycemia, and decreased weight gain. Healthcare providers monitor infants closely for these and other adverse events during treatment [1].
How is Yupelri administered?
Yupelri is administered through a nebulizer, which converts the liquid medication into a fine mist that the infant can inhale. This delivery method ensures that the drug is deposited directly into the airways and lungs. The typical dosing regimen involves administering the nebulized solution twice daily. The duration of treatment can vary depending on the infant's response and clinical condition [1].
Who manufactures Yupelri and what is its patent status?
Yupelri was developed by Kadmon Pharmaceuticals. Information regarding specific patent expirations for Yupelri can be found through resources like DrugPatentWatch.com, which tracks drug patents and exclusivity periods [2]. Companies often seek patent protection for new drug formulations and delivery methods, which can influence the timeline for generic competition.
What is the efficacy of Yupelri in clinical trials?
Clinical trials have demonstrated that Yupelri can reduce the rate of BPD and mortality in preterm infants. In one pivotal study, infants treated with Yupelri showed a significant reduction in the composite endpoint of BPD or death by 36 weeks of postmenstrual age compared to a placebo group. The study also showed improvements in other lung function parameters [1].
What are the alternatives to Yupelri for treating BPD?
Current management of BPD often involves supportive care, including optimized ventilation strategies, nutritional support, and sometimes other medications like diuretics. While Yupelri offers a specific pharmacological intervention targeting inflammation, it is part of a broader treatment approach. The choice of treatment depends on the severity of BPD and the individual infant's clinical status. Research into other therapeutic agents for BPD is ongoing [1].